Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past
four decades. Initially, computed tomography (CT) and then magnetic resonance imaging …

Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. At the
time of clinical manifestation of dementia, significant irreversible brain damage is already …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of …

The gap between symptoms and pathology in Alzheimer's disease has been explained by
the hypothetical construct of “cognitive reserve”—a set of variables including education …

Cerebral amyloid beta (Aβ) deposition occurs in a substantial fraction of cognitively normal
(CN) older individuals. However, it has been difficult to reliably detect evidence of amyloid …

Alzheimer's disease (AD) is the leading cause of dementia, accounting for 60–70% of all
cases [Hebert et al., 2003, 1]. The need for effective therapies for AD is great. Current …

Purpose Amyloid PET tracers have been developed for in vivo detection of brain fibrillar
amyloid deposition in Alzheimer's disease (AD). To serve as an early biomarker in AD the …

High levels of education, occupational complexity, and/or premorbid intelligence are
associated with lower levels of cognitive impairment than would be expected from a given …

In the field of ageing and dementia, brain-or cognitive reserve refers to the capacity of the
brain to manage pathology or age-related changes thereby minimizing clinical …

Recently published guidelines suggest that the most opportune time to treat individuals with
Alzheimer's disease is during the preclinical phase of the disease. This is a phase when …